These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 17910895)
1. Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells. Zagon IS; Rahn KA; McLaughlin PJ Neuropeptides; 2007 Dec; 41(6):441-52. PubMed ID: 17910895 [TBL] [Abstract][Full Text] [Related]
2. Opioids and differentiation in human cancer cells. Zagon IS; McLaughlin PJ Neuropeptides; 2005 Oct; 39(5):495-505. PubMed ID: 16169076 [TBL] [Abstract][Full Text] [Related]
3. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. Zagon IS; McLaughlin PJ Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586 [TBL] [Abstract][Full Text] [Related]
4. Opioids and the apoptotic pathway in human cancer cells. Zagon IS; McLaughlin PJ Neuropeptides; 2003 Apr; 37(2):79-88. PubMed ID: 12747939 [TBL] [Abstract][Full Text] [Related]
5. Direct effects of delta opioid receptor agonists on invasion-associated activities of HCT-8/E11 colon cancer cells. Debruyne D; Leroy A; DE Wever O; Vakaet L; Mareel M; Bracke M Anticancer Res; 2010 Jan; 30(1):9-17. PubMed ID: 20150612 [TBL] [Abstract][Full Text] [Related]
6. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606 [TBL] [Abstract][Full Text] [Related]
7. Reepithelialization of the human cornea is regulated by endogenous opioids. Zagon IS; Sassani JW; McLaughlin PJ Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):73-81. PubMed ID: 10634604 [TBL] [Abstract][Full Text] [Related]
8. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Zagon IS; Verderame MF; Hankins J; McLaughlin PJ Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915 [TBL] [Abstract][Full Text] [Related]
9. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Donahue RN; McLaughlin PJ; Zagon IS Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450 [TBL] [Abstract][Full Text] [Related]
10. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers. Zagon IS; McLaughlin PJ Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893 [TBL] [Abstract][Full Text] [Related]
11. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Jaglowski JR; Zagon IS; Stack BC; Verderame MF; Leure-duPree AE; Manning JD; McLaughlin PJ Cancer Chemother Pharmacol; 2005 Jul; 56(1):97-104. PubMed ID: 15791460 [TBL] [Abstract][Full Text] [Related]
12. Presynaptic actions of opioid receptor agonists in ventromedial hypothalamic neurons in estrogen- and oil-treated female mice. Devidze N; Zhang Q; Zhou J; Lee AW; Pataky S; Kow LM; Pfaff DW Neuroscience; 2008 Apr; 152(4):942-9. PubMed ID: 18343595 [TBL] [Abstract][Full Text] [Related]
13. Opioid growth factor regulates the cell cycle of human neoplasias. Zagon IS; Roesener CD; Verderame MF; Ohlsson-Wilhelm BM; Levin RJ; McLaughlin PJ Int J Oncol; 2000 Nov; 17(5):1053-61. PubMed ID: 11029512 [TBL] [Abstract][Full Text] [Related]
14. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Donahue RN; McLaughlin PJ; Zagon IS Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. McLaughlin PJ; Verderame MF; Hankins JL; Zagon IS Int J Mol Med; 2007 Mar; 19(3):421-8. PubMed ID: 17273790 [TBL] [Abstract][Full Text] [Related]
16. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy. Wang R; Zhang Y; Shan F Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891 [TBL] [Abstract][Full Text] [Related]
17. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Blumenthal RD; Hansen HJ; Goldenberg DM Cancer Res; 2005 Oct; 65(19):8809-17. PubMed ID: 16204051 [TBL] [Abstract][Full Text] [Related]
19. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. McLaughlin PJ; Jaglowski JR; Verderame MF; Stack BC; Leure-Dupree AE; Zagon IS Int J Oncol; 2005 Mar; 26(3):809-16. PubMed ID: 15703840 [TBL] [Abstract][Full Text] [Related]
20. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium. Zagon IS; Ruth TB; McLaughlin PJ Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]